Professor David Lalloo

Vice-Chancellor of Liverpool School of Tropical Medicine and Professor of Tropical Medicine

David Lalloo is a clinical academic in Tropical Medicine and Infectious Diseases with a a particular interest in clinical trials and epidemiological studies in LMICs. Having undergone initial training in Newcastle upon Tyne, David trained in General (Internal) Medicine, Infectious Diseases and Tropical Medicine, spending three years in Papua New Guinea. He undertook clinical and laboratory research in Oxford before moving as Senior Lecturer to the Liverpool School of Tropical Medicine in 1999. Prior to taking up the Directorship of LSTM in January 2019, David was Dean of Clinical Sciences and International Public Health and was Director of the Wellcome Trust Liverpool Glasgow Centre for Global Health Research and the Liverpool Wellcome Trust Clinical PhD Programme. He holds an appointment as an Honorary Consultant at the Royal Liverpool University Hospital and remains clinically active.

His research has focused particularly on HIV related infections, malaria and envenoming and he has also worked on COVID. He has active collaborations in a number of countries including Malawi, Uganda, Sri Lanka, Vietnam, Kenya, Nigeria, eSwatini, Ghana, Sierra Leone and South Africa. He has worked with the MLW Programme in Malawi for over twenty years and has a strong interest in identifying and supporting young UK and African clinicians interested in tropical research and strengthening scientific capacity in resource poor settings.

David has held a number of national roles. He chaired the DHSC COVID-19 Prophylaxis Oversight group and was an advisor to a number of DHSC, FDCO/DfID, NIHR and NICE COVID-19 groups. He currently chairs the NIHR Global Health Advisory Group, has been a member of the Medical Research Council Global Health group for over 10 years and was previously a member of SAGE for Ebola and Zika. He chaired the PHE Advisory Committee on Malaria from 2010-2019. He has sat on multiple funding committees and was Chair of the Wellcome Trust/ MRC/ DfID/DH Clinical Trials PaneI from 2016-2019.

In May 2024, David was elected as a new Fellow of the Academy of Medical Sciences.

Research

His research focuses on clinical trials and epidemiological studies of HIV related infections, malaria and envenoming. He has also worked extensively on COVID in the last three years. He has active collaborations in a number of countries including Malawi, Uganda, Sri Lanka, Vietnam, Kenya, Nigeria, eSwatini, Ghana, Sierra Leone and South Africa. He has particularly worked with the MLW Programme in Malawi for over twenty years and has a strong interest in identifying and supporting young UK and African clinicians interested in tropical research and strengthening scientific capacity in resource poor settings.

Other relevant expertise, professional memberships

Chair: DHSC COVID 19 Prophylaxis Oversight Group (2020-23)
Advisor to COVID 19 Therapeutic Task Force and Antiviral Task Force (2020-22)
Member of NICE Rapid C19 Group (2022)
Chair: NIHR Global Health Research (GHR) Independent Scientific Advisory Group (2018-)
Chair: Public Health England Advisory Committee on Malaria Prevention in Travellers (2010- 2019)
Medical Research Council Global Health Advisory Group (2010 - 2020)
Chief Medical Officer Scientific Advisory Group (SAGE) on Zika (2016)
Chief Medical Officer Scientific Advisory Group on Emergencies (SAGE) for Ebola (2014- 5)
Public Health England Expert Advisory Group on Anti-venoms, (2010- )
Honorary Consultant Advisor for Tropical medicine for the Army (2021- )
National Poisons Service Advisor on Envenoming (2011-)
Joint Committee on Vaccination and Immunisation Travel Sub-group (2010- 2019)
Chair of a number of international Trial Steering and Data Monitoring Committees

Science Funding Panel Membership

Chair: Wellcome Trust/MRC/DfID/DH Clinical Trials PaneI (2016-2019, member since 2009- )
MRC Applied Global Health Research Board (2020-)
UKRI Future Leaders Panel (2020- )
African Academy of Sciences DELTA Panel (2020)
Wellcome Trust Science Interview Panel (2015-2019)
MRC/DFID African Research Leader Panel (2010-)
NIHR Global Health Research Groups and Unit Panel (2016-2020)
Wellcome Trust Panel on Ebola Interventions (2014-5)
MRC Infection and Immunity Board (2010 to 2015)
Meningitis Research Foundation Scientific panel (2008 to 2016)

Examples of current and recent grants/projects

Project Title	Role	Awarding Body	Amount	Grant period
Multi-centre antivenom trial in Africa	Principle Applicant	Wellcome Trust	£13,700,000	2023-2028
African Snakebite Alliance	Principle Applicant	Wellcome Trust	£4,487,365	2023-2028
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment’	Co-applicant	Wellcome Trust	£3,069,077	2021-2023
AGILE: Seamless Phase I/IIa Platform for Rapid Evaluation of Candidates for COVID-19 treatment	Co-applicant	MRC	£3,749,054	2021-2023
Mapping Snakebite Risk in sub-Saharan Africa	PhD Fellowship	Wellcome Trust	£365,204	2021-2023
Lassa fever near-patient PCR and haemostasis diagnostics	PhD Fellowship	Wellcome Trust	£336,054	2021-2023
Antivenom clinical trial development	Principal Applicant	Wellcome Trust	£192,258	2018-2021
Trials Methodology Research Partnership	Co-applicant	MRC	£383,080	2018-2022
Defining the pathophysiology of snakebite induced local tissue damage	PhD Fellowship	Wellcome Trust	£350,000	2018-2021
NIHR Group on African Snakebite Research	Co-applicant	NIHR	£2,000,000	2017-2018
Health in a changing climate: snake bite in South Asia	Principal Applicant	MRC	£512,000	2017-2018
High Dose AMBISOME Cryptococcal Meningitis in SSA	Co-applicant	EDCTP	£8,500,000	2017-2022

Recent publications:

Selected publications

Abouyannis M, Esmail H, Hamaluba M et al, (Lalloo DG senior author of 26 authors). A global core outcome measurement set for snakebite clinical trials; Lancet Glob Health. 2023 Feb;11(2):e296-e300. doi: 10.1016/S2214-109X(22)00479-X.

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. Jarvis JN, Lawrence DS, Meya DB et al, (Lalloo DG 40th of 42 authors). N Engl J Med. 2022 Mar 24;386(12):1109-1120. doi: 10.1056/NEJMoa2111904.

Walker PGT, Whittaker C, Watson OJ et al (Lalloo DG 47th of 49 authors). Ferguson NM, Ghani AC. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020 Jul 24;369(6502):413-422. doi: 10.1126/science.abc0035.

Molloy SF, Kanyama C, Heyderman RS et al (Lalloo DG 32nd of 37 authors). Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018 Mar 15;378(11):1004-1017. doi: 10.1056/NEJMoa1710922

Molloy SF, Kanyama C, Heyderman RS et (Lalloo DG 33^rd/36 authors). Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018 Mar 15;378(11):1004-1017..doi: 10.1056/NEJMoa1710922. PubMed PMID: 29539274

Beardsley J, Wolbers M, Kibengo FM et al, (Lalloo DG 30th of 31 authors); CryptoDex Investigators. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med. 2016 Feb 11;374(6):542-54. doi: 10.1056/NEJMoa1509024.

MacPherson P, Lalloo DG, Webb EL et al. , Effect of optional home initiation of HIV care following HIV self-testing on antiretroviral therapy initiation among adults in Malawi: a randomized clinical trial. JAMA. 2014 Jul 23-30;312(4):372-9. doi: 10.1001/jama.2014.6493

Day JN, Chau TT, Wolbers M et al. (Lalloo DG joint senior author). Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013 Apr 4;368(14):1291-302. doi: 10.1056/NEJMoa1110404

Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A , Kenya Mugisha N, Grosskurth H , Kamali A, Lalloo DG. Primary prophylaxis of cryptococcal disease using fluconazole in HIV positive Ugandan adults - a double blind, randomised, placebo controlled trial. Lancet Infectious Diseases. 2011 Dec;11(12):933-41.

Ajdukiewicz KM, Cartwright KE, Scarborough M, Mwambene JB, Goodson P, Molyneux ME, Zijlstra EE, French N, Whitty CJ, Lalloo DG. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial (link is external). Lancet Infectious Diseases. 2011 Apr;11(4):293-300

De Silva HA, Pathmeswaran A, Jayamanne S, Samarakone SMSB, Hittharage A, Kalupahana R, Ratnathilake A, Uluwatte W, Ranasinha CD, Aronson JK, Armitage J, Lalloo DG, De Silva HJ. Promethazine, hydrocortisone, and low-dose adrenaline (alone and in combination) in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double blind, placebo-controlled trial. PLOS Medicine. 2011 May; 8(5):e1000435

Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, Savioli L, Lalloo DG, de Silva HJ. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008 Nov 4;5 (11):e218. doi:10.1371/journal.pmed.0050218.